The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to provide a significant substantial decrease in body mass and enhance metabolic funct